LGCYX vs. VKTX

Last updated Apr 1, 2026

Compare and contrast key facts about Lord Abbett Global Equity Fund (LGCYX) and Viking Therapeutics, Inc. (VKTX).

LGCYX is managed by Lord Abbett. It was launched on Jan 17, 2017.

Performance

LGCYX vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lord Abbett Global Equity Fund (LGCYX) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

LGCYX vs. VKTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LGCYX Lord Abbett Global Equity Fund	-6.41%	21.73%	17.83%	23.59%	-18.91%	2.29%	23.72%	26.72%	-9.34%	18.55%
VKTX Viking Therapeutics, Inc.	-7.50%	-12.57%	116.23%	97.98%	104.35%	-18.29%	-29.80%	4.84%	88.42%	181.94%

Returns By Period

In the year-to-date period, LGCYX achieves a -6.41% return, which is significantly higher than VKTX's -7.50% return.

LGCYX

• 1D: -0.48%
• 1M: -8.19%
• YTD: -6.41%
• 6M: -4.63%
• 1Y: 16.01%
• 3Y*: 15.78%
• 5Y*: 5.59%
• 10Y*: —

VKTX

• 1D: 8.76%
• 1M: -3.84%
• YTD: -7.50%
• 6M: 23.82%
• 1Y: 34.74%
• 3Y*: 25.03%
• 5Y*: 38.96%
• 10Y*: 36.40%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LGCYX vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LGCYX

LGCYX Risk / Return Rank: 49
LGCYX Sharpe Ratio Rank: 46
LGCYX Sortino Ratio Rank: 47
LGCYX Omega Ratio Rank: 45
LGCYX Calmar Ratio Rank: 52
LGCYX Martin Ratio Rank: 53

VKTX

VKTX Risk / Return Rank: 59
VKTX Sharpe Ratio Rank: 58
VKTX Sortino Ratio Rank: 59
VKTX Omega Ratio Rank: 63
VKTX Calmar Ratio Rank: 56
VKTX Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LGCYX vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lord Abbett Global Equity Fund (LGCYX) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LGCYX	VKTX	Difference
Sharpe ratio Return per unit of total volatility	0.93	0.44	+0.49
Sortino ratio Return per unit of downside risk	1.39	1.10	+0.29
Omega ratio Gain probability vs. loss probability	1.20	1.17	+0.03
Calmar ratio Return relative to maximum drawdown	1.27	0.60	+0.67
Martin ratio Return relative to average drawdown	5.23	1.32	+3.91
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LGCYX vs. VKTX - Sharpe Ratio Comparison

The current LGCYX Sharpe Ratio is 0.93, which is higher than the VKTX Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of LGCYX and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LGCYX	VKTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.93	0.44	+0.49
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.31	0.39	-0.07
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.37	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.53	0.12	+0.41

Correlation

The correlation between LGCYX and VKTX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LGCYX vs. VKTX - Dividend Comparison

LGCYX's dividend yield for the trailing twelve months is around 0.77%, while VKTX has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
LGCYX Lord Abbett Global Equity Fund	0.77%	0.72%	0.65%	1.06%	0.96%	1.07%	5.07%	1.34%	5.46%	5.85%
VKTX Viking Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

LGCYX vs. VKTX - Drawdown Comparison

The maximum LGCYX drawdown since its inception was -36.30%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for LGCYX and VKTX.

Drawdown Indicators

	LGCYX	VKTX	Difference
Max Drawdown Largest peak-to-trough decline	-36.30%	-90.41%	+54.11%
Max Drawdown (1Y) Largest decline over 1 year	-10.69%	-45.14%	+34.45%
Max Drawdown (5Y) Largest decline over 5 years	-36.30%	-78.86%	+42.56%
Max Drawdown (10Y) Largest decline over 10 years	—	-89.26%	—
Current Drawdown Current decline from peak	-9.99%	-65.57%	+55.58%
Average Drawdown Average peak-to-trough decline	-8.58%	-59.92%	+51.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.60%	20.31%	-17.71%

Volatility

LGCYX vs. VKTX - Volatility Comparison

The current volatility for Lord Abbett Global Equity Fund (LGCYX) is 5.82%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 18.20%. This indicates that LGCYX experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LGCYX	VKTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.82%	18.20%	-12.38%
Volatility (6M) Calculated over the trailing 6-month period	10.60%	45.65%	-35.05%
Volatility (1Y) Calculated over the trailing 1-year period	16.99%	78.68%	-61.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	17.86%	101.68%	-83.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.26%	99.00%	-80.74%